BioCentury

8:00 AM GMT, Dec 17, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

OxThera: A two-for-one offer

By concentrating on two forms of a single indication for which no therapeutics are available and few are in development, OxThera AB is hoping to corner the Orphan market for primary hyperoxaluria and maintain a role in the larger secondary hyperoxaluria indication.

Primary hyperoxaluria is a rare genetic disease affecting about 2,000 patients in the U.S. and Europe, resulting

Read the full 597 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.